Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20201951 | 1.00 | TSHR (0.30) | TSHR | |
| SCHEMBL14379071 | 0.84 | TSHR (0.31) | TSHR | |
| SCHEMBL20201400 | 0.84 | TSHR (0.31) | TSHR | |
| SCHEMBL20204627 | 0.84 | TSHR (0.31) | TSHR | |
| SCHEMBL20207645 | 0.79 | — | — | |
| SCHEMBL10909379 | 0.77 | — | — | |
| SCHEMBL6378031 | 0.77 | PKM (0.42) | — | |
| SCHEMBL20201458 | 0.65 | — | — | |
| SCHEMBL12570736 | 0.65 | — | — | |
| SCHEMBL7044026 | 0.65 | PIK3CD (0.42) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506294-B1 | HYDANTOIN RACEMASE | DSM IP ASSETS BV (NL) | 2006-03-29 | — | — | EP | claimed |
| US-7713724-B2 | polypeptides with hydantoin racemase activity that do not suffer from substrate inhibition; for racemization of D- or L-hydantoins | DSM IP ASSETS B.V. (NL) | 2010-05-11 | — | — | US | disclosed |
| EP-1506294-B1 | HYDANTOIN RACEMASE | DSM IP ASSETS BV (NL) | 2006-03-29 | — | — | EP | disclosed |
| US-20060035321-A1 | Hydantoin racemase | DSM IP ASSETS B.V. (NL) | 2006-02-16 | — | — | US | disclosed |
| EP-1506294-A1 | HYDANTOIN RACEMASE | DSM IP Assets B.V. (NL) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003100050-A1 | HYDANTOIN RACEMASE | DSM IP ASSETS B.V. (NL) | 2003-12-04 | — | — | WO | disclosed |
| EP-0400638-B1 | Process for the preparation of D-alpha aminocarboxylic acids | DEGUSSA (DE) | 1994-10-05 | — | — | EP | disclosed |
| US-4980284-A | Method of preparing D-α-amino acids | DEGUSSA AG (DE) | 1990-12-25 | — | — | US | disclosed |
| EP-0400638-A1 | Process for the preparation of D-alpha aminocarboxylic acids | DEGUSSA AG (DE) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035321-A1 | Hydantoin racemase | IMPDH2, IMPDH1, DIMT1 | TSHR 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.